June 17, 2026 | Featured on Clinical Lab Projects
LabConnect Scientific Expert Featured in Clinical Lab Products Article on Alzheimer’s Blood Testing
Joe Marino, vice president, global scientific services at LabConnect, shared insights with Clinical Lab Products on the importance of sample handling, processing time, storage conditions, and protocol compliance in Alzheimer’s blood testing.
As Alzheimer’s blood-based biomarker testing continues to advance, clinical laboratories and research teams must look beyond analytical performance alone. Preanalytical variability, including differences in specimen handling, anticoagulants, time to processing, cold-chain management, and storage, can affect biomarker stability and reproducibility across sites.
In this article, Joe Marino, vice president, global scientific services, notes that biomarkers such as Aβ can degrade quickly when processing is delayed, which may impact test accuracy. He also highlights the importance of high-throughput, standardized, and automated laboratory processes as Alzheimer’s blood testing scales toward broader clinical and research adoption.
Read the full article in Clinical Lab Products to learn more about the operational, analytical, and clinical considerations shaping the future of Alzheimer’s blood testing.
Read the Article
Supporting References
- Arnett, A. (2026, June 17). A Year of Firsts for Alzheimer’s Blood Testing. Clinical Lab Products.
https://clpmag.com/disease-states/dementias-alzheimer/alzheimers-blood-testing-fda-clearance-guidelines-2025/ - Weber DM, Taylor SW, Lagier RJ, et al. Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer’s disease assessment. Front Neurol. 15:1364658.
- Li Y, Lagier RJ, Racke MK, et al. Cost-effectiveness analysis of blood-based biomarker testing in the diagnosis of Alzheimer’s disease pathology. J Prev Alzheimers Dis. 2026;13(3):100474.
- Palmqvist S, Whitson HE, Allen LA, et al. Alzheimer’s Association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings. Alzheimers Dement. 2025;21(7):e70535.
- Hu M, Knopman DS, Therneau T, et al. Breakpoints in Alzheimer’s disease biomarkers and cognition across the aging spectrum: The Mayo Clinic study of aging. Alzheimers Dement. 2026;22(4):e71227.
Joe Marino, Vice President, Global Scientific Services, LabConnect
Joe is a scientific and operational leader with extensive technical expertise in analytical development, bioanalytical operations, clinical trial laboratory strategy, and global sample management. He has held roles across research, quality analytical services, bioanalytical services, and scientific operations.
At LabConnect, Joe supports scientific strategy and operational execution for complex global studies, helping sponsors navigate the evolving needs of biomarker-driven clinical development while supporting high-quality sample and data outcomes.
Questions? Ask Our Experts!
Contact us today to learn more or schedule a consultation.
Let’s Get Started
Explore how you can accelerate your clinical trial with LabConnect’s end-to-end central lab services and functional service provider solutions.
